Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 219,937,504 papers from all fields of science
Search
Sign In
Create Free Account
telatinib
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Broader (2)
Pyridazines
Pyridines
Receptor Tyrosine Kinase Inhibition
Telatinib Mesylate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
chapter 4 – skin microvascular density and blood pressure Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib Anticancer Drugs
M. P. Boer
,
A. Veldt
,
+5 authors
E. Serné
2015
Corpus ID: 14784289
Hypertension is a common side-effect in cancer patients treated with inhibitors of VEGF/VEGFR-2 signaling and may represent a…
Expand
Review
2014
Review
2014
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
Yi-Jun Wang
,
Yun-kai Zhang
,
Rishil J. Kathawala
,
Zhe-Sheng Chen
Cancers
2014
Corpus ID: 13938006
The phenomenon of multidrug resistance (MDR) has attenuated the efficacy of anticancer drugs and the possibility of successful…
Expand
2012
2012
The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors
B. Benjamin
,
M. Sahu
,
U. Bhatnagar
,
D. Abhyankar
,
N. Srinivas
Arzneimittelforschung/Drug Research
2012
Corpus ID: 404897
Abstract Literature data on the clinical pharmacokinetics of various VEGFR-2 inhibitors along with in vitro potency data were…
Expand
2011
2011
Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with…
M. Alsina
,
A. Ko
,
+6 authors
J. Ajani
Journal of Clinical Oncology
2011
Corpus ID: 5949568
4122 Background: Angiogenesis is essential for tumor growth and plays an important role in metastasis in gastrointestinal (GI…
Expand
2010
2010
Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction…
A. Ko
,
J. Tabernero
,
+7 authors
J. Ajani
2010
Corpus ID: 75675650
e14575 Background: Telatinib (T) is a potent small molecule oral tyrosine kinase inhibitor selectively targeting the VEGF and…
Expand
2010
2010
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
M. Langenberg
,
P. Witteveen
,
+7 authors
E. Voest
2010
Corpus ID: 74596400
3045 Background: Telatinib (BAY 57-9352) is an oral tyrosine kinase inhibitor targeting the vascular endothelial growth factor…
Expand
2008
2008
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors
P. Witteveen
,
M. Langenberg
,
+7 authors
E. Voest
2008
Corpus ID: 75886481
2530 Background: Telatinib is an orally available, small molecule tyrosine kinase domain inhibitor of the VEGFR-2, VEGFR-3, PDGFR…
Expand
2007
2007
Clinical and biomarker responses in a Phase I continuous dose study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in patients with colorectal carcinoma
K. Mross
,
M. Scheulen
,
+6 authors
D. Strumberg
2007
Corpus ID: 87934144
B87 Background: Telatinib (BAY 57-9352) inhibits VEGFR-2, VEGFR-3, PDGFR-β and c-Kit receptor tyrosine kinases. Telatinib showed…
Expand
2007
2007
A phase Ib study of telatinib (BAY 57–9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumours
H. Shaw
,
L. R. Molife
,
+7 authors
J. Bono
2007
Corpus ID: 70631213
14035 Background: Telatinib (BAY 57–9352) inhibits VEGFR-2 and VEGFR-3 tyrosine kinases, and PDGFR-β and c-Kit. Preclinical data…
Expand
2007
2007
A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors
H. Shaw
,
R. Molife
,
+9 authors
J. Bono
2007
Corpus ID: 86361939
B13 Background: Telatinib (BAY 57-9352) is an oral, multitargeted tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, PDGFR-I² and c…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required